Please use this identifier to cite or link to this item:
Title: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial
Austin Authors: Gleeson, Mary;Hawkes, Eliza A ;Cunningham, David;Chadwick, Nick;Counsell, Nicholas;Lawrie, Anthony;Jack, Andrew;Smith, Paul;Mouncey, Paul;Pocock, Christopher;Ardeshna, Kirit M;Radford, John;McMillan, Andrew;Davies, John;Turner, Deborah;Kruger, Anton;Johnson, Peter WM;Gambell, Joanna;Linch, David
Affiliation: Austin Health, Heidelberg, Victoria, Australia
The Royal Marsden Hospital, London and Surrey, UK
Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Eastern Health, Melbourne, Victoria, Australia
Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK
East Kent Hospitals, Canterbury, UK
University College London, London, UK
Mount Vernon Cancer Centre, Northwood, UK
The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Nottingham City Hospital, Nottingham, UK
Western General Hospital, Edinburgh, UK
Torbay Hospital, Torquay, UK
Royal Cornwall Hospital, Truro, UK
Cancer Research UK Centre, Southampton, UK
Issue Date: 1-Aug-2016 2016-08-01
Publication information: British Journal of Haematology 2016; online first: 1 August
Abstract: We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.
DOI: 10.1111/bjh.14287
PubMed URL:
Type: Journal Article
Subjects: Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Type of Clinical Study or Trial: Clinical Trial
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 7, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.